DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Contribución de congreso (ConferenceOutput)
Thioaryl imides, a novel familiy of potential SARS-COV-2 entry inhibitors identified through a high thoughput pseudotyped assay
Resumen del póster presentado a las IV Jornadas Científicas PTI+ Salud Global, celebradas del 28 al 29 de octubre de 2024 en el Auditorio Marie Curie – Parc Científic de la Unviersitat de València., Background. Although the WHO declared the end of the COVID-19 emergency in May 2023, the
disease remains as a global public health threat and complete eradication of the causative agent, the
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains an elusive goal in the short
to medium term1. Fortunately, this lethal pandemic has been controlled by the emergence of vaccines
capable of inducing neutralizing antibodies that efficiently block infection. These vaccines were
developed using revolutionary mRNA technical breakthroughs based on harmless fragments of the
spike-shaped S protein (S-Protein). It must be noted that it is well established that SARS-CoV-2 infects
cells through the interaction of the S-protein located on the surface of the virus with the angiotensin
converting enzyme 2 (ACE2) cell receptors.
In spite of these success, the main concerns regarding the contemporary clinical landscape of the
disease are the emergence of new variants, particularly focused on mutations in the S-protein. Since
the identification of the original Wuhan strain, there have been multiple variants of concern, like the
Omicron variants, which evolved into five lineages, among them the XBB1.5, the currently most
prevalent subvariant due to its enhanced immune evasion from protection provided by prior infections
or vaccines. This emphasize the importance of identifying and developing new chemotherapeutics,
including small molecules, to combat COVID infection by targeting the entry of the virus into the host
cells as a still attractive strategy whether the antivirals under investigation are adapted to the
prevalent S-protein variants2., Methods. High-throughput screening (HTS) assays based on pseudotyped vesicular stomatitis viruses
expressing the currently prevailing S-protein of SARS-CoV-2 (VSV-S) can be considered as simple,
reliable platforms for the rapid identification of novel compounds with potential as entry inhibitors
(hits)3. We report herein the preliminary evaluation of a small chemical library on VSV-S
pseudoparticles harboring the XBB.1.5 S protein in Vero E6 cells expressing the TMPRSS2 entry factor., Results. A library of 30 synthetic thioaryl imides provided by IQM were assayed by I2SysBio in this
HTS platform. Evaluated compounds proved a noticeable ability to inhibit the virus attachment to the
host cells, showing IC50 values in the range 0.2-7.0 µM whereas keeping selectivity indexes >10., Conclusions. The screening campaign allowed to identify a series of potential SARS-CoV-2 entry
inhibitors (XBB.1.5). The most active molecule showed significant capability to selectively block the
interaction between ACE2 and pseudotyped VSV-S (IC50=0.2 µM). Moreover, thioaryl imides are a
largely unexplored family of chemicals. These promising results could encourage us to explore focused research aimed at providing a candidate with enhanced activity and improved properties for further evaluation., The Spanish Ministry of Science and Innovation AEI/10.13039/501100011033 (grants PID2022-136307OB- C21 and PID2022-137372OR-C22 (MICINN/AEI/10.13039/501100011033/ FEDER, UE) and NextGeneration (EU 2020/2094) CSIC Global Health Platform (PTI Salud Global) are acknowledged for financial support., No